A CASE REPORT: THE ROLE OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN LABELED THERANOSTIC AGENTS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Yıl 2019, Cilt: 6 Sayı: 1, 0 - 0, 01.02.2019

Ali Rıza Avul Büşra Özdemir Gülay Durmuş Altun

Öz

Aims: Prostate cancer is one of the most prevalent cancers worldwide and sometimes it can be deadly which brings out a high quantity of the prostate specific membrane antigen. Gallium-68 prostate specific membrane antigen PET scan is used to detect primary tumors and metastases of prostate cancer. In addition, Lutetium-177 prostate-specific membrane antigen is used for treatment in some special cases. Our case report aims to show the roles of prostate specific membrane antigen labeled theranostic agents in the diagnosis, staging, and treatment of prostate cancer and evaluate the response to the treatment of metastatic castration-resistant prostate cancer.

Case Report: A 78-year-old male patient was admitted to Trakya University Hospital Nuclear Medicine Department with the diagnosis of prostate cancer for cancer staging and treatment. Gallium-68 prostate specific membrane antigen was firstly used to detect any metastases and then to evaluate response to the treatment. Lutetium-177 prostate specific membrane antigen was used for treatment.

Conclusion: After 3 cures of Lutetium-177 therapy, the patient underwent Gallium - 68 prostate specific membrane antigen PET which demonstrated regression of the metastatic tumor. There was a decrease in the uptake of Gallium-68 prostate specific membrane antigen in the primary tumor and lymph nodes metastases. Also, bone metastases have been cleared. Hence, Lutetium-177 seems to be a promising treatment modality to treat metastatic prostate cancer. 

Anahtar Kelimeler

Prostate cancer, theranostic, lutetium

Kaynakça

• 1. Mottet N, Bellmunt J, Briers E et al. Guidelines on prostate cancer, 2015. Available from: URL: https:// uroweb.org/wp-content/uploads/09-Prostate-Cancer_ LR.pdf.
• 2. American Cancer Society. Cancer facts & figures 2018. Available from: URL: https://www.cancer. org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
• 3. Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol 2017;35:1-13.
• 4. Teo MY, Morris MJ. Prostate-specific membrane antigen-directed therapy for metastatic castration-resistant prostate cancer. Cancer J 2016;22(5):347-52.
• 5. Giesel FL, Fiedler H, Stefanova M et al. PSMA PET/ CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga (HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42(12):1794-800.
• 6. Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value ofPET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42(2):197-209.
• 7. Durmuş Altun-Üstün (2017) Nükleer Tıp Görüntüleme Teknikleri Ders Kitabı: Nobel Tıp Kitapevleri, 2017.
• 8. Emmett L, Willowson K, Violet J et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64(1):52-60.
• 9. Udovicich C, Perera M, Hofman M et al. 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends. Prostate International 2017;5(4):125-9.
• 10. Ahmadzadehfar H, Wegen S, Yordanova A et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA. Eur J Nucl Med Mol Imaging 2017;44(9):1448-54.
• 11. Rauscher I, Maurer T, Fendler WP et al. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging 2016;16:14.
• 12. Kabasakal L, Toklu T, Yeyin N. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther 2017;26(2):62-8.